Alivus Life Sciences shareholding pattern

·Pharma & HealthChart ›

Who owns itSep 2026 quarter

Promoters74.85%−0.02 pts
Foreign investors (FII)5.93%+0.39 pts
Domestic institutions (DII)7.03%−0.15 pts
of which mutual funds5.29%−0.36 pts
of which insurance companies0.24%
Public12.19%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group82.8575.0075.0074.9974.9474.9174.9174.8774.8774.85
FII / FPI4.827.856.746.576.426.845.095.295.545.93
DII1.574.164.865.195.615.477.127.287.187.03
Mutual Funds1.012.823.233.594.063.875.445.635.655.29
Latest: 2026-09-30 · 22 quarters of history · click a row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.